Loading
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Latest quote
$85.49
−$4.59 · -5.10%
After-hours
$85.49
$0.00 · 0.00%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Day range
Current $85.49
52-week range
Current $85.49
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
28
Expensive
Sentiment
70
Bullish
Risk
47
Elevated Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Day range
Current $85.49
52-week range
Current $85.49
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 167K USD | — | — | — | — |
| Gross profit | −167K USD | — | — | — | — |
| Research and development | 145M USD | 104.2M USD | 60.59M USD | 35.29M USD | 25.76M USD |
| Selling, general, and administrative | 27.2M USD | 9.06M USD | 5.64M USD | 4.38M USD | 2.6M USD |
| Operating expenses | 172.19M USD | 113.27M USD | 66.23M USD | 39.39M USD | 28.36M USD |
| Interest income | 12.3M USD | 11.77M USD | 7.78M USD | 1.13M USD | 13.26K USD |
| Interest expense | 17.15M USD | 10.28M USD | 5.33M USD | 2.11M USD | 1.26M USD |
| Depreciation and amortization | 167K USD | 129.95K USD | 142.77K USD | 210.92K USD | 303.24K USD |
| Operating income | −172.19M USD | −113.27M USD | −66.23M USD | −39.39M USD | −28.36M USD |
| Net income | −177.04M USD | −111.78M USD | −63.78M USD | −40.37M USD | −29.61M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$154.33
80.52% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI120.83M0.01%2.3T USD0.03%$373.24-0.62%
State Street SPDR S&P Biotech ETFXBI110.06M0.97%11.33B USD0.35%$156.82-1.61%
iShares Russell 2000 ETFIWM88M0.11%80.51B USD0.19%$287.7-1.01%
Vanguard Extended Market ETFVXF37.83M0.04%93.7B USD0.05%$236.16-1.05%
iShares Russell 2000 Growth ETFIWO32.51M0.22%14.7B USD0.24%$365.67-1.42%
Vanguard Russell 2000 ETFVTWO18.65M0.10%17.4B USD0.06%$116.34-1.00%
Schwab U.S. Small-Cap ETFSCHA16.39M0.07%22.62B USD0.03%$33.65-1.32%
Fidelity Enhanced Small Cap ETFFESM5.7M0.09%6.49B USD0.28%$46.00-1.18%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
